ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
ERBB2	2064	16710036	-	Amplification	-	-	-	483	17 to 89	62	Arthur James Cancer Hospital of the Ohio State University Medical School	I (n=289); II (n=46); III (n=109); IV (n=39)	1 (n=184); 2 (n=116); 3 (n=63)	[1] HER-2 is an important oncogene in high grade and stage endometrial cancer; but plays only a minor role in the much more common low grade and stage tumors that encompass the majority of clinical practice. [2] Both expression and amplification of HER-2 was associated with high-grade (P = .0001) and high stage (P = .0001) endometrial cancer. The highest rate of HER-2 expression and amplification was seen in serous carcinoma (43% and 29%); while grade 1 endometrioid adenocarcinoma showed the lowest levels (3% and 1%). For all histologic types; the rate of HER-2 expression and amplification was remarkably different (P < .0001) for grade 3 cancers (31% and 15%) versus grade 2 (7% and 3%) and grade 1 cancers (3% and 1%); with similar results for endometrioid type (P < .0001).	HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients	Jounral of Clinical Oncology	24(15):2376-85	2006
ERBB2	2064	17549377	-	Up regulation/ Over expression/High expression	-	-	12 (n=2; proliferative; n=2; secretory phase; n=8; atrophic endometria)	25	50 to 80	61	Second Department of Gynecology; Lublin University School of Medicine; Lublin; Poland	I (n=20); II (n=1); III (n=2); IV (n=2)	1 (n=7); 2 (n=11); 3 (n=7)	[1] erbB-2 mRNA was overexpressed in 8% (2/25) of the analysed tumors. [2] The level of expression appeared to be significantly higher in the malignant tumors as compared to the benign ones for erbB-2 (p=0.008; respectively). Concomitant erbB-1 and erbB-2 overexpression was detected only in 1 out of 25 (4%) uterine neoplasms. The data suggest that erbB-1/erbB-2 overexpression is a direct effect of higher than normal transcriptional activity of the encoding genes in a subset of human endometrial carcinomas.	Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium.	Oncology Reports	18(1):261-5	2007
ERBB2	2064	8104681	Endometrial adenocarcinoma + Papillary Serous carcinoma	-	-	-	-	32 (Endometrial adenocarcinoma) + 2 (Papillary Serous carcinoma)	-	-	-	I (n=17); II (n=4); III (n=13)	1 (n=12); 2 (n=14); 3 (n=6)	[1] The expression of EGFR in addition to c-erbB-2 protein is more frequently observed with advancing stage of disease and is inversely correlated with the grade of differentiation and with the expression of ER or PR of the tumor. [2] Of the 34 endometrial carcinomas; 22 (64.7%) were cerbB-2 protein-positive and EGFR-negative; 8(23.5%) were positive for both c-erbB-2 protein andEGFR; and the remaining 4 were negative forboth proteins. Of the 22 patients with c-erbB-2 proteinpositiveand EGFR-negative disease; 12 had FIGOStage I(12 of 17 Stage I; 70.6%); 2 had Stage I1 (2 of 4Stage 11; 50%); and 8 had Stage 111 disease (8 of 13 Stage111; 61.5%). Of the eight patients with c-erbB-2 proteinpositiveand EGFR-positive disease; two had Stage 1(2of 17 Stage I; 11.8%); one had Stage I1 (1 of 4 Stage 11;25%); and five had Stage I11 disease (5 of 13 Stage 111;38.5%)	Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.	Cancer	72(9):2628-37	1993